Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification. Netsirisawan P, Chaiyawat P, Chokchaichamnankit D, Lirdprapamongkol K, Srisomsap C, Svasti J, Champattanachai V*. Oncol Rep. 2018 Oct;40(4):2193-2205.

01 Oct 2018
0
0

Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification.

Netsirisawan P, Chaiyawat P, Chokchaichamnankit D, Lirdprapamongkol K, Srisomsap C, Svasti J, Champattanachai V*.

Oncol Rep. 2018 Oct;40(4):2193-2205.

Tags

Share this

Related Posts

The combination of arginine deprivation and 5-fluorouracil improves therapeutic efficacy in argininosuccinatesynthetase negative hepatocellular carcinoma. Thongkum, A., Wu, C., Li, Y. Y., Wangpaichitr, M., Navasumrit, P., Parnlob, V., Savaraj, N. (2017). International Journal of Molecular Sciences, 18(6).
01 Jun 2017
0

The combination of arginine deprivation and 5-fluorouracil improves therapeutic efficacy in argininosuccinatesynthetase negative hepatocellular carcinoma. Thongkum, A., Wu, C., Li, Y. Y., Wangpaichitr, M., Navasumrit, P., Parnlob, V., Savaraj, N. (2017). International Journal of Molecular Sciences, 18(6).

The combination of arginine deprivation and 5-fluorouracil improves therapeutic efficacy in argininosuccinatesynthetase negative hepatocellular carcinoma. Thongkum, A., Wu, C., Li, Y. Y., Wangpaichitr, M., Navasumrit, P., Parnlob, V., Savaraj, N. (2017). International Journal of Molecular Sciences, 18(6).
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
New
20 Sep 2023
0
New

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More